Compare STC & TLX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
| Metric | STC | TLX |
|---|---|---|
| Founded | 1893 | 2015 |
| Country | United States | Australia |
| Employees | N/A | N/A |
| Industry | Specialty Insurers | Biotechnology: Pharmaceutical Preparations |
| Sector | Finance | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 2.2B | 2.2B |
| IPO Year | 1994 | N/A |
| Metric | STC | TLX |
|---|---|---|
| Price | $67.49 | $6.56 |
| Analyst Decision | Buy | Strong Buy |
| Analyst Count | 2 | 4 |
| Target Price | ★ $81.00 | $21.00 |
| AVG Volume (30 Days) | 199.3K | ★ 203.5K |
| Earning Date | 05-07-2026 | 01-01-0001 |
| Dividend Yield | ★ 3.16% | N/A |
| EPS Growth | ★ 135.14 | N/A |
| EPS | ★ 2.79 | N/A |
| Revenue | ★ $2,490,419,000.00 | N/A |
| Revenue This Year | $13.62 | N/A |
| Revenue Next Year | $7.13 | N/A |
| P/E Ratio | ★ $23.75 | $150.33 |
| Revenue Growth | ★ 10.33 | N/A |
| 52 Week Low | $56.39 | $6.28 |
| 52 Week High | $78.61 | $19.93 |
| Indicator | STC | TLX |
|---|---|---|
| Relative Strength Index (RSI) | 44.24 | 41.78 |
| Support Level | $65.10 | $6.28 |
| Resistance Level | $73.15 | $10.02 |
| Average True Range (ATR) | 1.97 | 0.24 |
| MACD | -0.25 | 0.03 |
| Stochastic Oscillator | 18.54 | 16.05 |
Stewart Information Services Corp is a customer-focused, title insurance and real estate services company offering products and services to home buyers and sellers, mortgage lenders and servicers, attorneys, and home builders. It has three operating segments; Title insurance and related services which generates key revenue, includes the functions of searching, examining, closing, and insuring the condition of the title to real property. It also includes home and personal insurance services, Real estate solutions segment supports the real estate mortgage industry by providing appraisal management services, online notarization and closing solutions, credit, and real estate information services, search and valuation services. Corporate and other segment is comprised of parent holding company.
Telix develops radiopharmaceuticals to manage cancer. Radiopharmaceuticals are radioisotopes bound to molecules that can target specific cells. At low doses, these drugs can bind to specific cancer cells with radiation, and then positron emission tomography imaging can accurately visualize tumors. At high doses, these drugs can selectively target and treat tumors with radiation, known as radioligand therapy. Radiopharmaceuticals are usually injected into the bloodstream. Telix has a pipeline of potential radiopharmaceuticals but currently earns most of its revenue from US sales of Illuccix, largely used as an imaging agent to visualize the spread of prostate cancer.